Zentiva Group a.s.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Will Try Camurus’s FluidCrystal D

Four biosimilars sponsors – Biocon Biologics, Gedeon Richter, Mabxience and Zentiva – have each received dual positive opinions from the European Medicines Agency’s Committee for Medicinal Products fo

Zentiva has revealed the result of its previously-announced bid to take control of “single pill company” Apontis Pharma – and the outcome is positive for the buyer, with Zentiva’s voluntary public pur

Zentiva has responded to rumors that owner Advent could be looking to sell the firm, with a recent Bloomberg report suggesting that Advent is exploring options and valuing a potential deal at €5bn (